trending Market Intelligence /marketintelligence/en/news-insights/trending/0ryTgHbF_H9x7fQNtvjEyw2 content esgSubNav
In This List

Menlo Therapeutics itch drug gets US FDA breakthrough therapy status

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Menlo Therapeutics itch drug gets US FDA breakthrough therapy status

Menlo Therapeutics Inc.'s medicine serlopitant has been granted the U.S. Food and Drug Administration's breakthrough therapy designation to treat a type of skin disease.

The Redwood City, Calif-based pharmaceutical company said serlopitant was granted the status to treat pruritus, or itching associated with prurigo nodularis, a skin disease characterized by itchy swellings on the arms and legs. The company's request for the breakthrough therapy designation was supported by positive results from a mid-stage study.

The FDA's breakthrough therapy status allows for expedited development and review of drugs that show improvement compared to existing therapies for treating a serious or life-threatening disease.

Menlo is enrolling patients in two phase 3 studies of serlopitant for treating pruritus associated with prurigo nodularis and plans to evaluate the drug to treat itching associated with psoriasis in a separate late-stage study. The company's development program for the drug also includes a mid-stage study for chronic pruritus of unknown origin.